International Journal of Neonatal Screening (Mar 2024)

Expanded Newborn Screening for Inborn Errors of Metabolism in Hong Kong: Results and Outcome of a 7 Year Journey

  • Kiran Moti Belaramani,
  • Toby Chun Hei Chan,
  • Edgar Wai Lok Hau,
  • Matthew Chun Wing Yeung,
  • Anne Mei Kwun Kwok,
  • Ivan Fai Man Lo,
  • Terry Hiu Fung Law,
  • Helen Wu,
  • Sheila Suet Na Wong,
  • Shirley Wai Lam,
  • Gladys Ha Yin Ha,
  • Toby Pui Yee Lau,
  • Tsz Ki Wong,
  • Venus Wai Ching Or,
  • Rosanna Ming Sum Wong,
  • Wong Lap Ming,
  • Jasmine Chi Kwan Chow,
  • Eric Kin Cheong Yau,
  • Antony Fu,
  • Josephine Shuk Ching Chong,
  • Ho Chung Yau,
  • Grace Wing Kit Poon,
  • Kwok Leung Ng,
  • Kwong Tat Chan,
  • Yuen Yu Lam,
  • Joannie Hui,
  • Chloe Miu Mak,
  • Cheuk Wing Fung

DOI
https://doi.org/10.3390/ijns10010023
Journal volume & issue
Vol. 10, no. 1
p. 23

Abstract

Read online

Newborn screening (NBS) is an important public health program that aims to identify pre-symptomatic healthy babies that will develop significant disease if left undiagnosed and untreated. The number of conditions being screened globally is expanding rapidly in parallel with advances in technology, diagnosis, and treatment availability for these conditions. In Hong Kong, NBS for inborn errors of metabolism (NBSIEM) began as a pilot program in October 2015 and was implemented to all birthing hospitals within the public healthcare system in phases, with completion in October 2020. The number of conditions screened for increased from 21 to 24 in April 2016 and then to 26 in October 2019. The overall recruitment rate of the NBS program was 99.5%. In the period between October 2015 and December 2022, 125,688 newborns were screened and 295 were referred back for abnormal results. The recall rate was reduced from 0.26% to 0.12% after the implementation of second-tier testing. An inherited metabolic disorder (IMD) was eventually confirmed in 47 infants, making the prevalence of IMD in Hong Kong 1 in 2674. At the time of the NBS result, 78.7% of the newborns with IMD were asymptomatic. There were two deaths reported: one newborn with methylmalonic acidemia cobalamin B type (MMACblB) died after the initial crisis and another case of carnitine palmitoyltransferase II deficiency (CPTII) died at 18 months of age after metabolic decompensation. The most common IMD noted were disorders of fatty acid oxidation metabolism (40%, 19 cases), closely followed by disorders of amino acid metabolism (38%, 18 cases), with carnitine uptake defect (19.1%, 9 cases) and citrullinemia type II (17%, 8 cases) being the two most common IMD picked up by the NBSIEM in Hong Kong. Out of the all the IMDs identified, 19.1% belonged to diverse ethnic groups. False negative cases were reported for citrullinemia type II and congenital adrenal hyperplasia during this period.

Keywords